The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Sleep Apnea Symptoms Linked to Memory and Thinking Problems Mar. 4, 2024 — People who experience sleep apnea may be more likely to also have memory or thinking problems, according to a ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Postmenopausal sleep issues contribute to a sharp decline in sleep quality among older women, beginning at approximately 51 ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...

Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 ...

The FDA said studies have shown that by aiding weight loss, Zepbound helps reduce sleep apnea symptoms in some patients. In ...